CommercialCoverageLow impact
06.02.29d, AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (Independence Administrators)
Independence Blue Cross·Cardiology, Cardiothoracic Surgery·Pharmacy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Independence Administrators has reissued policy 06.02.29d regarding AlloMap™ Molecular Expression Testing for Heart Transplant Rejection, effective March 5, 2025. This is a commercial policy update that may affect billing procedures for heart transplant monitoring services.
Action Required
By March 5, 2025: Review the complete policy details at the provided URL to understand any changes to AlloMap™ testing coverage and billing requirements. This primarily affects practices that treat heart transplant patients and bill for molecular expression testing services.